Mounjaro (Tirzepatide) SURPASS Program Highlights infographic Video

VMA English

Overview

Mounjaro effect in Type 2 Diabetes: an overview of the SURPASS Trails Program.

This Class for

  • Clinical Pharmacy
  • Pharmacy
  • Physician
  • Resident / Fellow

What I will learn?

Shed light on the unsurpassed results of Mounjaro across 5 phase 3 SURPASS trail, were studying Tirzepatide vs. placebo and different active comparators in participants with Type 2 Diabetes.





Disclaimer

This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
(This information/content is intended to Health Care Providers only)

For adverse events and safety reporting: email: [email protected]
24 /7 mobile : +966 567 868 843 working hours: +966 11 461 7800 , Ext: 1
For Lilly product information: email: [email protected]
For further information, please contact:
Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: [email protected]

Please go to PDF Material for prescribing information



PP-TR-SA-0053
  • clock Last Update 08/2023
  • adjust VMA